Adaptimmune Therapeutics Dirección
Dirección controles de criterios 3/4
Adaptimmune Therapeutics' El consejero delegado es Ad Rawcliffe , nombrado en Sep 2019, tiene un mandato de 4.25 años. la remuneración anual total es $3.41M , compuesta por 19.1% salario y 80.9% primas, incluidas acciones y opciones de la empresa. posee directamente 0.07% de las acciones de la empresa, por valor de $79.67K . La antigüedad media del equipo directivo y del consejo de administración es de 4.3 años y 8.8 años respectivamente.
Información clave
Ad Rawcliffe
Chief Executive Officer (CEO)
US$3.4m
Compensación total
| Porcentaje del salario del CEO | 19.1% |
| Permanencia del CEO | 4.6yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 4.3yrs |
| Promedio de permanencia en la Junta Directiva | 9.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22
Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth
Apr 15Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%
Mar 15Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?
Feb 17
Have Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Been Selling Their Stock?
Jan 22Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
Jan 15Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Enjoyed An Impressive 227% Share Price Gain
Dec 11Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$114m |
| Sep 30 2023 | n/a | n/a | -US$95m |
| Jun 30 2023 | n/a | n/a | -US$91m |
| Mar 31 2023 | n/a | n/a | -US$114m |
| Dec 31 2022 | US$3m | US$650k | -US$165m |
| Sep 30 2022 | n/a | n/a | -US$175m |
| Jun 30 2022 | n/a | n/a | -US$176m |
| Mar 31 2022 | n/a | n/a | -US$171m |
| Dec 31 2021 | US$4m | US$617k | -US$158m |
| Sep 30 2021 | n/a | n/a | -US$156m |
| Jun 30 2021 | n/a | n/a | -US$149m |
| Mar 31 2021 | n/a | n/a | -US$140m |
| Dec 31 2020 | US$3m | US$574k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$123m |
| Jun 30 2020 | n/a | n/a | -US$127m |
| Mar 31 2020 | n/a | n/a | -US$138m |
| Dec 31 2019 | US$2m | US$500k | -US$137m |
| Sep 30 2019 | n/a | n/a | -US$144m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$102m |
| Dec 31 2018 | US$1m | US$457k | -US$96m |
| Sep 30 2018 | n/a | n/a | -US$87m |
| Jun 30 2018 | n/a | n/a | -US$93m |
| Mar 31 2018 | n/a | n/a | -US$69m |
| Dec 31 2017 | US$2m | US$444k | -US$70m |
Compensación vs. Mercado: Ad($USD3.41M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).
Compensación vs. Ingresos: Adha sido coherente con los resultados de la empresa en el último año.
CEO
Ad Rawcliffe (51 yo)
4.6yrs
Permanencia
US$3,408,527
Compensación
Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 4.6yrs | US$3.41m | 0.10% $ 308.4k | |
| Chief Financial Officer | 4yrs | US$1.32m | 0.0063% $ 18.6k | |
| Chief Operating Officer | 7.1yrs | US$1.39m | 0.064% $ 190.5k | |
| Chief Medical Officer | 4.3yrs | US$1.77m | 0.037% $ 109.8k | |
| Chief Commercial Officer | less than a year | US$2.19m | 0.021% $ 63.1k | |
| Co-Founder & Chief Business & Strategy Officer | no data | US$1.78m | 0.12% $ 348.2k | |
| Chief Scientific Officer | 1.9yrs | sin datos | 0.0049% $ 14.4k | |
| VP of Corporate Affairs & Investor Relations | no data | sin datos | sin datos | |
| Senior VP & General Council | 8.5yrs | sin datos | sin datos | |
| Senior Director of Corporate Communications | no data | sin datos | sin datos | |
| Chief Patient Supply Officer | 4.7yrs | US$1.72m | 0.053% $ 158.0k | |
| Senior Vice President of Late Stage Development | 4.3yrs | sin datos | sin datos |
4.3yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: ADAPEl equipo directivo de la empresa se considera experimentado (4.3 años de antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, Principal Accounting Officer & Director | 4.6yrs | US$3.41m | 0.10% $ 308.4k | |
| Independent Chairman of the Board of Directors | 9.2yrs | US$208.54k | 0% $ 0 | |
| Independent Non-Executive Director | 9.2yrs | US$153.64k | 0% $ 0 | |
| Independent Non-Executive Director | 9.1yrs | US$170.11k | 0.0094% $ 27.7k | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 5.8yrs | US$161.73k | 0% $ 0 | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos |
9.1yrs
Permanencia media
58.5yo
Promedio de edad
Junta con experiencia: La junta directiva de ADAP se considera experimentada (8.8 años de antigüedad promedio).